
|Videos|October 7, 2017
CD101: A New Long-Acting Echinocandin
Author(s)Contagion® Editorial Staff
David Andes, MD, shares the half-life and dosing intervals for a new long-acting echinocandin.
Advertisement
David Andes, MD, professor and chief of infectious disease at the University of Wisconsin, shares the half-life and dosing intervals for a new long-acting echinocandin.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Advertisement
Advertisement
Advertisement
Trending on Contagion Live
1
Dynavax and Vaxart Partner to Advance Oral COVID-19 Vaccine
2
Using Doxycycline for Post-Exposure Prevention of Lyme Disease in Young Kids
3
FDA Clears Immuron’s IMM-529 For Clinical Testing in C difficile; Phase 2 Set to Begin in Australia
4
Clesrovimab Lowers RSV Hospitalizations and Illness in Healthy Infants
5

































































































































































































































































































